Dr. Scheffer C. G. Tseng co-founded TissueTech and Bio-Tissue and is currently Chief Tecnology Officer for TissueTech and Chairman of the company’s Board of Directors. Dr. Tseng is a world-renowned surgeon in ocular surface reconstruction and a widely published physician scientist with more than 300 peer-reviewed clinical and scientific papers. He pioneered limbal stem cell transplantation and developed and commercialized the CryoTek process to preserve the natural therapeutic properties of amniotic membrane. His research focus for the past 30 years has been to identify the biological components of human placental tissues, to develop alternative products to deliver their natural therapeutic properties, and to expand their clinical applications. Dr. Tseng holds a medical degree from National Taiwan University and a Doctorate in Experimental Pathology from the University of California. He completed his residency in ophthalmology at the Wilmer Eye Institute at Johns Hopkins, and his fellowship in cornea and external diseases at Massachusetts Eye and Ear Infirmary. Prior to co-founding TissueTech, Dr. Tseng was a Chair Professor at Bascom Palmer Eye Institute, University of Miami School of Medicine.
Amy Tseng is TissueTech’s Chief Executive Office and a member of the company’s Board of Directors. Amy co-founded Bio-Tissue in 1997 and TissueTech in 2001 with the vision of commercializing cryopreserved amniotic membrane as a platform technology for the treatment of ocular surface diseases. Since its inception, Amy has presided over this mission, building Bio-Tissue into the industry leader in this sector and spearheading the founding of Amniox Medical to expand the Company’s technology into other healthcare sectors. She has guided the company through impressive levels of annual growth. Prior to founding Bio-Tissue, Amy spent 10 years with the big five accounting firms, Ernst & Young and Price Waterhouse. Amy holds a Master of Business Administration from the University of Southern California.
Prior to joining Ballast Point Ventures in 2004, Matt Rice began his career in the Health Care Investment Banking Group of Raymond James Financial, where he focused primarily on the specialty pharmaceutical, drug distribution and contract research organization sectors. Matt also worked in the Strategic Alliances group at the Novartis Institutes for BioMedical Research prior to rejoining Ballast Point Ventures as a Vice President in 2008.
In addition to serving on the Board of Directors of TissueTech, Matt currently serves on the Board of Directors at MolecularMD, Y-Prime, MeYou Health, Theragen, Iconixx, IRIS, and previously represented BPV at Innocutis. Matt leads Ballast Point Venture’s health care practice and also serves on the St. Joseph’s Hospitals Board of Directors (Baycare Health System). Matt holds a Bachelor’s Degree in Commerce from the University of Virginia and a Master of Business Administration from the Harvard Graduate School of Business Administration.
Marty Sutter is the co-founder of EW Healthcare Partners (originally called Essex Woodlands), which he established in 1985. Mr. Sutter has been instrumental in leading EW’s healthcare growth equity investment practice and serves as Chairman of the firm’s Investment Committee.
Mr. Sutter has been directly involved with more than 30 EW portfolio companies. He has led and served on the Boards of Directors of numerous EW investments including ATS Medical (acquired by Medtronic), BioForm Medical (acquired by Merz GmbH), Lifecell (acquired by Kinetic Concepts), St. Francis Medical (acquired by Kyphon), and Abiomed. Mr. Sutter currently serves on the Board of Directors of EW portfolio companies Bioventus, Prolacta and TissueTech. And continues to serve on the Board of Directors of Abiomed.
In addition to the portfolio company boards, Mr. Sutter formerly served on the Board of Trustees of The Culinary Institute of America and was the past Chairman of The Texas Lyceum.
Mr. Sutter holds a Bachelor of Science degree from Louisiana State University and a Master of Business Administration degree from the University of Houston.
Bill Hawkins joined EW Healthcare Partners as Senior Advisor in the New York office in 2017. Mr. Hawkins serves on the board of EW portfolio companies Bioventus and TissueTech.
Mr. Hawkins has decades of experience in building dynamic and innovative healthcare companies and is among the business leaders in the healthcare industry. Mr. Hawkins is a retired Chairman and CEO of Medtronic, a global innovative medical device company with $100 billion market capitalization.
Prior to Medtronic, Mr. Hawkins served as President and Chief Executive Officer of medical device company Novoste Corporation, where he led the development of the company’s innovative stents. Previously, he held senior leadership positions at American Home Products, Johnson & Johnson, Guidant Corporation and Eli Lilly & Company. He began his medical technology career with Carolina Medical Electronics in 1977.
Mr. Hawkins has actively served on multiple public and private, as well as non-profit boards. He currently serves as Chairman and previously served as President and CEO of Immucor, a leading global provider of transfusion and transplantation diagnostic products, backed by TPG. He is also the past Chairman and Co-Founder of the Medical Device Innovation Consortium (“MDIC”), and past President of the American Institute of Medical and Biological Engineering (“AIMBE”). He serves as a Director of Avanos Health (NYSE: AVNS) and 4-Tech, a cardiology startup in Ireland, Trice Medical, Cerius, Cirtec, Virtue Labs, Baebies, AskBio, Focused Ultrasound Society and Biogen.
At his alma mater, Mr. Hawkins was elected to the Duke University Board of Trustees in 2011 and currently serves on the Executive Committee as the Vice Chairman of the Board. He is on the Audit and Compliance Committee, and the Advancing Duke Science and Technology Task Force. He is also Chair of the Board of the Duke University Health System.
Mr. Hawkins received his Bachelor’s degree in Electrical and Biomedical Engineering from Duke University in 1976, and an MBA from the Darden School of Business, University of Virginia, in 1982.
John Arnott was most recently Operating Partner and Executive Chairman of multiple portfolio companies for The Riverside Company, one of largest and oldest global private equity firms. Mr. Arnott’s career in healthcare dates back four decades and has an extensive background in corporate, private equity, international, regional, and country operating environments, including senior positions with Idex Corporation, Alpine Biomed, Sierra Scientific, and Abbott Laboratories.
John’s career launched in 1977 when he began work for the National Health Service in the United Kingdom, ultimately serving as Chief Medical Laboratory Scientific Officer for the Welsh National Blood Transfusion Service. From 1990 to 2003, he held several executive positions at Abbott Laboratories, including Vice President and Regional Director of European Operations and corporate Vice President of the Hospital Products Division. Before joining Riverside, he served as Chief Executive Officer & Chairman of Alpine Biomed, Executive Chairman of Sierra Scientific and President of Idex Health & Science LLC.